期刊文献+

脑钠肽与狼疮性肾炎患者心脏损害关系研究 被引量:4

原文传递
导出
摘要 目的:探讨脑钠肽与狼疮性肾炎患者合并心脏损害的关系。方法:选择62例狼疮性肾炎患者和35例健康体检者(对照组),分别行超声心动图检查,测量其左心室舒张末期内径、左心室射血分数、左心室心肌质量指数,同时测定血浆脑钠肽、白蛋白、肌酐等水平;观察脑钠肽与左心室舒张末期内径、左心室射血分数、左心室心肌质量指数、白蛋白、肌酐的关系。结果:狼疮性肾炎组脑钠肽水平明显高于对照组(P<0.01),合并心脏损害的狼疮患者脑钠肽明显高于不合并心脏损害组(P<0.01)。脑钠肽水平与左心室舒张末期内径、左心室心肌质量指数呈正相关(r=0.54,P<0.01;r=0.46,P<0.01);与左心室射血分数呈负相关(r=-0.72,P<0.01)。结论:脑钠肽测定有助于发现并监测狼疮性肾炎合并心脏损害。
出处 《中华实用诊断与治疗杂志》 2011年第6期599-600,共2页 Journal of Chinese Practical Diagnosis and Therapy
  • 相关文献

参考文献5

  • 1Sudoh T, Kangawa K, Minamino N, et al. A new natriurctic peptidein porcine Brain[J]. Nature, 1988,332(6159):78-81.
  • 2LeeS C, Stevens T L, Sandberg S M, et al. The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure [J]. J CardiolFail,2002,8(3):149-154.
  • 3付海霞,张嘉莹,李庚山,许家俐.慢性心力衰竭患者血浆脑钠肽水平研究[J].实用诊断与治疗杂志,2006,20(10):705-707. 被引量:25
  • 4Wang A Y, Lam C W, Yu C M, et al. N-terrninal pro brain natriuretic peptide : an independent risk predictor of cardiovascular congestion, mortality, adverse cardiovascular outcomes in chronic peritoneal dialysis patients[J]. J Am Soc Nephrol,2007,18(1) :321- 330.
  • 5Iwanaga Y, Nishi I, Furuchi S, et al. B-type natriuratic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure[J]. Am CollCardiol,2006,47(4):742 -748.

二级参考文献11

  • 1Vuolteenaho O, Ala-Kopsala M, Ruskoaho H. BNP as a biomarker in heart disease[J]. Adv Clin Chem,2005,40(1):1.
  • 2Dries D L, Stevenson L W. Brain natriuretic peptide as bridge to therapy for heart failure[J]. Lancet, 2000,355(9210):1112.
  • 3Tsutamoto T, Wada A, Sakai H, et al. Relationship between renal function and plasma brain natriuretic peptide in patients with heart failure[J]. J Am Coll Cardiol, 2006,47(3):582.
  • 4Maeda K, Tsutamoto T, Wada A, et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular enddiastolic pressure in patients with symptomatic left ventricular dysfunction[J]. Am Heart J, 1998,135(5Pt):825.
  • 5Morrison L K, Harrison A, Krishnaswamy P, et al. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea[J]. J Am Coll Cardiol, 2002,39(2):202.
  • 6Maisel A S, Koon J, Krishnaswamy P, et al. Utility of Bnatriuretie peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction[J]. Am Heart J, 2001,141 (3): 367.
  • 7Task force for the diagnosis and treatment of chronic heart failure of European. Society of cardiology. Guidelines for the diagnosis and treatment of chronic heart failure[J]. Eur Heart J,2001,22(17):1527.
  • 8Yu C M, Sanderson J E, Shum I O, et al. Diastolic dysfunction and natriuretic peptides in systolic heart failure. Higher ANP and BNP levels are associated with the restrictive filling pattern[J]. Eur Heart J,1996,17(11):1664.
  • 9Selvais P L, Donckier J E, Robert A, et al. Cardiac natriuretic peptides for diagnosis and risk stratification in heart failure: influences of left ventricular dysfunction and coronary artery disease on cardiac hormonal activation[J]. Eur J Clin Invest, 1998,28(8):636.
  • 10Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study[J]. J Am Coll Cardiol, 2001,37 (2) : 386.

共引文献24

同被引文献31

  • 1曹兴建,郭新荣,管耘园.血浆B型钠尿肽测定在心功能衰竭诊断中的应用[J].临床检验杂志,2005,23(2):141-142. 被引量:17
  • 2Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction[ J]. N Engl J Med, 2006,355 (3); 251 -259.
  • 3Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study [ J ]. N Engl J Med,2006, 355 ( 3 ): 260-269.
  • 4Massie BM, Carson PE, McMurray JJ, et al. Irbesar-tan in patients with heart failure and preserved ejection fraction [ J]. N Engl J Med, 2008, 359 ( 23): 2456-2467.
  • 5Ahmed A, Rich MW, Fleg JL,et al. Effects of digo-xin on morbidity and mortality in diastolic heart failure :Circulation, 2006,114(5) : 397 -403.
  • 6Fitzgibbons TP,Meyer TE,Aurigemma GP. Mortality in diastolic heart failure an update [ J ] . Cardiol Rev, 2009,17(2) : 51 -55.
  • 7Triposkiadis F, Karayannis G,Giamouzis G,et al. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications [J]. J Am Coll Cardiol, 2009,54(19) : 1747 — 1762.
  • 8Paulus WJ,Tschope C,Sanderson JE,et al. How to diagnose diastolic heart failure : a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology [ J]. Eur Heart J, 2007, 28 ( 20 ): 2539-2550.
  • 9Wang JW, Kurrelmeyer KM, Torre-Amione G,et al. Systolie and diastolie dyssynchrony in patients with diastolic heart failure and the effect of medieal therapy [J]. J Am Coll Cardiol,2007,49( 1) ; 88 -96.
  • 10Jourdain P, Joudeau G, Funk F, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study[J]. J Am Coil Cardiol, 2007,49 (16) : 1733-1739.

引证文献4

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部